一两拳:结合化疗和免疫疗法,降低患有鼻癌的儿童和青少年的辐射剂量和相关毒性
Hetal Dholaria1,2,3, Vera Tsetlina4, Shae K Simpson5
1Department of Oncology, Perth Children's Hospital, Perth, Australia.
概括
儿科鼻癌治疗正在发展. 新的试验将化疗和免疫疗法与减少辐射相结合,以保持优良的生存率,同时尽量减少儿童癌症幸存者的长期副作用.
科学领域:
- 儿科瘤学 儿科瘤学
- 辐射瘤学 辐射瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 鼻癌在儿科患者中很罕见.
- 放射治疗对于治疗这种瘤至关重要,但会导致严重的长期副作用.
- 降低辐射剂量是限制幸存者的晚期影响的优先事项.
研究的目的:
- 为儿童鼻癌引入新的临床试验.
- 通过结合先进的化疗和免疫疗法来改善治疗策略.
- 为了降低辐射剂量和相关的毒性,同时保持高生存率.
主要方法:
- 使用诱导化疗和用抗PD-1药物的免疫疗法.
- 实施响应适应的,剂量降低的放射治疗.
- 在先前成功的儿科临床试验的基础上.
主要成果:
- 之前的试验表明,使用化疗,放射和干扰素免疫治疗的生存率很好.
- 新的方法旨在维护这些结果.
- 目标是限制与治疗相关的晚期效应和疾病.
结论:
- 化疗和免疫疗法与有针对性的,剂量降低的辐射的整合代表了显著的进步.
- 这一战略有望改善儿童癌症幸存者的生活质量.
- 未来的临床试验将评估这种新方法的疗效和安全性.
相关概念视频
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines
522
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
522
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
267
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
267


